Panacea Biotec gets manufacturing license for Sputnik V vaccine

05 Jul 2021 Evaluate

Panacea Biotec has received manufacturing license from Drugs Controller General of India (DCGI) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia’s sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India.

The batches produced at company’s facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

552.75 -10.90 (-1.93%)
30-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.20
Dr. Reddys Lab 1183.00
Cipla 1549.65
Lupin 2094.65
Zydus Lifesciences 887.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...